RMDI
REGN icon

R.M. Davis Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

R.M. Davis Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-281
Closed -$295K – 285
2024
Q3 		$295K Sell
281
-9
-3% -$10K 0.01% 234
2024
Q2 		$305K Sell
290
-7
-2% -$6.79K 0.01% 237
2024
Q1 		$286K Buy
297
+7
+2% +$6.66K 0.01% 230
2023
Q4 		$255K Hold
290
– – 0.01% 238
2023
Q3 		$239K Hold
290
– – 0.01% 248
2023
Q2 		$208K Buy
290
+45
+18% +$34.7K 0.01% 272
2023
Q1 		$201K Buy
+245
New +$185K 0.01% 269

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

R.M. Davis Inc's REGN Position: Q4 2024 in Review

R.M. Davis Inc sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 281 shares — an estimated $295K sold.

R.M. Davis Inc first reported a position in REGN in Q1 2023 and held it in 7 quarters. The position peaked at $305K in Q2 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • R.M. Davis Inc reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • R.M. Davis Inc sold 281 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $295K.
  • R.M. Davis Inc first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • R.M. Davis Inc's Regeneron Pharmaceuticals position peaked at $305K in Q2 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on R.M. Davis Inc's 13F filing for Q4 2024, filed 7 Feb 2025.